BMMCs contain much more subpopulations and are more active (Extended Data Fig. 1g-1j ).
Abstract
Integrated analyses of hematopoiesis and leukemogenesis could provide new biological and clinical insights 1, 2 . Here we constructed a comprehensive cell atlas using ~100,000 single cell transcriptomes of bone marrow mononuclear cells and its subsets from 5 healthy samples and 13 leukemia samples. Trajectory analysis showed hematopoietic stem cells continuously differentiated through tree-like structure into 7 lineages. Although our single cell analyses showed the major cellular heterogeneity were inter-patients, there were distinct leukemia cell subpopulations within patient. We developed counterpart composite index (CCI) for projecting leukemia cell subpopulation into reference hematopoietic cells, to identify their healthy counterparts that could predict leukemia subtype and clinical outcome. Interestingly, we found the trajectories of leukemogenesis were similar to that of their healthy counterparts, indicating lineage relationship of leukemia cell subpopulations.
Single cell analyses of leukemia patient at diagnosis, refractory, remission and relapse vividly presented dynamics of cell population and the underlying genes. Single cell transcriptomic variants analyses showed the relapsed leukemia cells, whose healthy counterparts were closer to the root of hematopoietic tree, were derived from an early minor leukemia cell population. This study not only increased our understanding of hematopoiesis and leukemogenesis, but also provided an approach for leukemia classification and clinical outcome prediction.
Main
Single cell RNA sequencing (scRNA-seq) provides unbiased gene expression profile of individual cells that is highly complementary to the immunological phenotypes approaches 3 . Recent massively parallel scRNA-seq enabled routine analyses of thousands of single cells for inferring the developmental trajectories [4] [5] [6] [7] [8] . In particular, single cell analysis of hematopoietic stem and progenitor cells (HSPCs) demonstrated hematopoiesis is a continuous process rather than discrete stepwise process [8] [9] [10] [11] [12] . However, inconsistency persists among those studies, e.g. Velten et al. proposed the CLOUD-HSPCs model in which HSPCs directly gave rise to distinct lineage-committed populations 9 , while Tusi et al. proposed a continuously hierarchies model 8 . Furthermore, the molecular mechanisms underlying hematopoietic lineage commitment remain poorly understood 10 .
Leukemia patients are still under the threat of relapse and drug resistance due to leukemia heterogeneity. Analyses of cancer stem cell in chronic myeloid leukemia identified distinct subpopulations of therapy-resistant stem cells 13 . Recent single cell study on acute myeloid leukemia (AML) revealed primitive leukemia cells aberrantly co-expressed stemness and myeloid priming genes 1 . However, our knowledge about the relationship of leukemia cell subpopulations and dynamic progression of leukemia are still limited. In this study, we constructed a comprehensive cell atlas of hematopoietic cells, and a hierarchically continuous transition model for hematopoiesis. We developed CCI to project leukemia cells to reference hematopoietic cells and identified the healthy counterparts of leukemia cell, which could predict leukemia subtype and clinical outcome. Single cell RNA-seq analysis of a patient at diagnosis, refractory, remission and relapse vividly demonstrated dynamics of leukemia progression.
Results

A comprehensive cell atlas of healthy BMMCs
Bone marrow is the primary tissue for blood cell production, and generates hundreds of billions of blood cells and immune cells per day. In order to gain further biological insights into hematopoiesis and leukemogenesis, we established approaches and pipelines for single cell analysis of BMMCs and its subsets from 5 healthy samples and 13 leukemia samples ( Fig. 1a, Extended Data Fig. 1a-1c and Table S1 ). The 18,751 cells from 4 healthy BMMCs were clustered into 17 distinct cell clusters using Louvain clustering algorithm and visualized by t-Distributed Stochastic Neighbor Embedding (tSNE) 14 (Fig. 1b) . We identified the cell type of each cluster based on their specific highly expressed genes ( Fig.   1c, 1d ). The frequencies of major identified cell types in BMMCs essentially consists with the expectations (Fig. 1b-1d ): 1.39% HSPCs (AVP+ and CD34+), 10.15% erythroid progenitor cells (EPCs) (GYPA+ and KLF1+), 0.08% megakaryocytes (Mk) (PF4+ and GP9+), 1.25% myelocytes (ELANE+ and MPO+), 2.91% monocytes (LYZ+ and CD14+), 17 .67% B cells (CD79A+), 53.11% T cells (CD3D+), 11.62% natural killer cells (NK) (FCGR3A+ and NCAM1+), 0.04% stromal cells (CXCL12+ and COL6A1+). Furthermore, the frequencies of cell types were highly consistent across different samples (r 2 =0.96; Extended Data Fig. 1e ).
Interestingly, we identified two distinct plasma cell populations both highly expressed SDC1, CD27 and TNFRSF17 (Fig. 1b, 1d) . Plasma cell #1 highly expressed IGHG1, IGHG2, IGHG3, IGHG4 and IGKC, while plasma cell #2 highly expressed IGHA1, IGHA2 and translation associated genes ( Fig. 1d, Extended Data Fig. 1d ), indicating their different cellular status and functions. We further identified a lot T cell subset in BMMCs (Extended Data Fig. 1f ). Compared with peripheral blood mononuclear cells (PBMCs) 15 , was derived from GMP while Ba/Eo/Ma lineage was derived from BMEP, different from classic hematopoietic model that granulocytes shared common progenitor 21, 22 .
Heatmap analysis showed the expression of early hematopoietic marker genes, such as AVP, HES1, CRHBP, MEG3, EMCN and HLF, are gradually decreasing along pseudotime ( Fig. 2d) . Although cells were clustered into different populations, their expressions do not show significant changes across the boundaries, further supporting gradually decrease of stemness along hematopoietic lineage. Attenuations of expression vary greatly from gene to gene, and different cells showed different gene expression patterns ( Fig. 2d) ,
indicating each cell with a unique status during hematopoiesis. Furthermore, by integrating HSPCs and BMMCs together (Extended Data Fig. 3b ), we constructed a much comprehensive cell atlas and hematopoietic lineages (Extended Data Fig. 3c, 3d) , in which HSPC located in the center while erythrocytes, lymphocytes and monocytes from BMMCs extended at terminal branch (Extended Data Fig. 3e ).
Lineage-coordinated genes, transcription factors (TFs) and networks
We identified thousands of lineage-coordinated genes with expression gradually shifting along hematopoietic lineages ( Fig. 2e; Extended Data Fig. 4a, 4b) . For instance, the expression level of CD79A, VPREB3 and PAX5 are increasing along the lymphoid (Lym) lineage ( Fig. 2e ). The observation that many genes changed continuously along the lineages further supports our presumption of hematopoiesis being a continuous process.
We further identified lineage coordinated TFs of each lineage using gene regulatory networks (GRN) scores 23 . Among the top 10 Lym lineage coordinated TFs (Fig. 2f) , process from HSC to distinct hematopoietic lineages ( Fig. 2j ). In this model, the hematopoietic system is a dynamic equilibrium system composed of a large number of transitional states/cells, among which contiguous ones could mutually convert into each other. Thus, the cell states were only affected by its previous states and compensation effect promotes the HSC transition to vacant slots. The cell fate of stem cell is not pre-defined but is gradually determined during the differentiation. Cells sorted by FACS can be treated as a continuum composed of a fraction of transitional states but lost other states. We could consider the classic step-wise model as a specific case of our continuous transition model, in which many transitional states have been missed. The continuous transition model bridges the gap between the classic step-wise models based on FACS sorting and recent continuous models based on single cell sequencing. This model provides an essential reference for understanding of leukemia heterogeneity and leukemogenic process.
Leukemia heterogeneity and shared features among patients
The molecular heterogeneity of the leukemia has significant impact on leukemia classification and treatment 25 . To characterize the heterogeneity of leukemia cells, we investigated the single cell transcriptomic data of BMMCs from 8 leukemia patients. tSNE projection showed these cells formed two kinds of clusters, either normal cell clusters with cells from both healthy and patient samples, or patient-specific clusters that only comprise of cells from single patient (Fig. 3a) . The results indicate leukemia cells were quite different from patient to patient, thus high interpatient heterogeneity. The expressions of hematopoietic lineage specific genes also support the uniqueness of patient-specific leukemia cells (Fig. 3b) . Compared with healthy BMMCs, the majority of the significantly upregulated gene sets or downregulated gene sets are patient specific, with only a few gene sets being shared among multiple patients ( Fig. 3c, 3d ).
Although leukemia cells exhibited a high heterogeneity among patients, identification of their shared features may provide important clinical implications for diagnosis and treatment. We noticed MIR181A1HG, ITGA4, CD96 and TXNP upregulated in 5 patients and no genes upregulated in all the 8 patients (Extended Data Fig. 5a ). There are a bunch of gene sets are commonly upregulated or commonly downregulated among all leukemia patients ( Fig. 3e) . The presence of many shared gene sets while absence of shared genes among all patients indicates patients are genetically specific but share signatures/pathways during cancer development. The most significantly upregulated signatures shared by these leukemia patients are IL2-STAT5 signaling, inflammation response, angiogenesis, IL6-JAK-STAT3 signaling, KRAS signaling, allograft rejection and hypoxia, which have been reported in various cancers, indicating these signatures played an important role in cancer development. The most significantly downregulated signatures shared by these leukemia patients are E2F targets, DNA repairs, reactive oxygen species pathway, MYC targets and G2M checkpoint, indicating reduced cell cycle checkpoint and decreased DNA repair activities play an import ant role in leukemia. Indeed, fraction of cells with active cell cycle in leukemia is much higher than that in healthy individual (Extended Data Fig. 5b-5e ), further indicating higher cell proliferation of leukemia cells.
Compared to healthy BMMCs, we observed the TF networks of ZNF266, RORA, GTF3C2, ZNF76, ZNF383, IRF5 and NFE2L2 being top up-regulated in all leukemia patients ( Fig.   3f ). RORA is the key regulator of embryonic development and cellular differentiation, whose up-regulation may promote the proliferation of the leukemia cells 26 . IRF5 promotes inflammation by activating genes producing interferons and cytokines 27, 28 . Upregulation of IRF5 network potentially indicates increase of inflammation in leukemia patients, although inflammation alone is inefficient to clean up leukemia cells. The top downregulated TF networks sharing among leukemia patients are RUNX3, KLF4, POU4F1, IKZF2, GTF3A, ATF4, TFDP1, GTF2A2, BCL11B, GFI1, MAZ, HDAC2 and KLF1 ( Fig. 3f) , majority of which are hematopoietic lineage specific, indicating that the healthy hematopoietic process was repressed in these leukemia patients. Heatmap analysis showed that upregulated TF networks and repressed TF networks were correlated, although the correlations of repressed TF networks were weaker than that between upregulated TF networks ( Fig. 3g) .
Searching healthy counterparts of leukemia cells to predict leukemia subtype and clinical outcome
Heterogeneity of the leukemia cells are associated with disease progression and reaction to chemotherapy 31, 32 . Identifying the leukemia cell subpopulations and inferring their origin could facilitate precise diagnosis and treatments. Here, we developed an approach, called counterpart composite index (CCI), to search for healthy counterpart of each leukemia cell subpopulation by projecting the leukemia cells into reference hematopoietic cell ( Fig. 4a) .
In order to improve the statistic power and accuracy, CCI integrates multiple statistics with difference measurements to project leukemia cells to healthy hematopoietic cells (see The substructure of leukemia cells is clearly visible and multiple leukemia cell subpopulations could be observed in each patient (Fig. 4b) . The healthy counterparts of leukemia cell subpopulations were different in the same patient and were different from patient to patient ( Fig. 4b,4c ). showed up in all the three ALL patients and the heterogeneity of leukemia cells in ALL is weaker than that in AML. Interestingly, we found the leukemia cells of two patients (AML027 and AML035) were projected into Ery lineage thus indicated different AML subtypes ( Fig. 4b,4c ). Furthermore, the abundances of leukemia cell subpopulations are quite different from patient to patient ( Fig. 4c) .
Interestingly, projections of the leukemia cells to reference hematopoietic lineages showed the leukemia cells from each patient occupy a flight of hematopoietic lineage ( Fig. 4d) , indicating a similar developmental trajectory between leukemia cells and their healthy counterparts. The leukemia cells from each ALL patient were projected to lymphoid lineage, which are consistent with the clinical diagnosis. The leukemia cells from different AML patients were project into the different myeloid lineages or the root of the hematopoietic tree, indicating the diversity of AML. The patients with leukemia cells projecting into the same hematopoietic lineage showed similar features, while patients with leukemia cells projecting into the same different hematopoietic lineage showed much different features. Therefore, Projection of leukemia cells into hematopoietic tree is an accurate and unbiased approach for leukemia classification. Furthermore, we found the patient with leukemia cells projecting to the root of the hematopoietic tree had the worst results.
Hypothesis about the origin of leukemia heterogeneity
Pseudotime inference of leukemia cells further showed that the trajectories of leukemia cell were similar to that of their healthy counterparts (Extended Data Fig. 5f ). In this way, we could assume that leukemia cell subpopulations are not a bunch of independent subpopulations but are a series of lineage-related cells in leukemogenesis. Therefore, we hypothesize the mutant leukemia initial cells or progenitors partially maintain its original developmental trajectory and terminate development at different stages due to loss of different functional genes, leading to a serial of dysfunctional leukemia cell subpopulations, instead of developing into a homozygous population.
Cell population dynamics of BMMCs in patient ALL3 and the underlying genes.
Patient ALL3, a 4 year old boy, was diagnosed with B-precursor ALL in Blood Diseases
Hospital, Chinese Academy of Medical Sciences (CAMS)/ Peking Union Medical College (PUMC) in Nov 2012 35 . The patient was refractory to a prolonged chemotherapy, and later achieved remission after Imatinib treatment. The patient relapsed and no longer responded to Imatinib treatment 5 months after remission ( Fig. 5a ). scRNA-seq data of BMMCs at diagnosis (ALL3.1), refractory (ALL3.2), remission (ALL3.3) and relapse (ALL3.4) were generated, which allowed us to investigate leukemia progression and the underlying mechanisms. By integrating healthy BMMCs and HSPCs as reference, leukemia cells could be easily distinguished from normal cells since leukemia cells are patient specific and normal cells are shared by all samples. Cells from healthy reference formed a notched circle on the tSNE projection ( Fig. 5b, 5c ), while leukemia cells formed several distinct clusters at the breach or inside of the notched circle ( Fig. 5b) . At diagnosis, leukemia cells account for 87.4% of total BMMCs and form a major cell cluster surrounding with some minor cell subpopulations ( Fig. 5d) . After prolonged chemotherapy, the percentage of leukemia cells in BMMCs slight decrease while the size of some surrounding minor cell subpopulation relatively increased ( Fig. 5e ). After Imatinib treatment, leukemia cells almost completely disappeared (~1.9%) during remission ( Fig.   5f ). However, the leukemia cells come back and become dominant (~82.7%) after relapse, with a significant reduction of normal cells ( Fig. 5g) . Especially, leukemia cells before and after relapse were projected to different coordinates of tSNE projection (Fig. 5b, 5g ), indicating the relapsed leukemia cells are quite different from the leukemia cells in the early stage. The relapsed leukemia cell has the highest fraction of cells in active cell cycle and has the highest entropy among all cell clusters (Fig. 5h, 5i and Extended Data Fig.   6a ), indicating the proliferation and transcriptional complexity of leukemia cells significantly increased after relapse. In summary, these results vividly showed the pronounced dynamics of leukemia cells during clinical treatments and relapse.
According to the above observation, we could conclude that leukemia cells experienced dramatic changes across time. Identifying the differentially expressed genes and pathways between pre-and post-relapse leukemia cells could enhance our understanding of relapse process. We identified 243 significantly upregulated genes and 79 significantly downregulated genes (fold change >2) after relapse (Fig. 5j) . The upregulated genes include H2AFY, IGLL1, GYPC, HSPB1, STT3B, C1QTN4, SUSD3 and PDLIM1 ( Fig.   5j ), which significant enriched in E2F targeted genes, G2M checkpoints, oxidative phosphorylation, MTORC1 signaling and so on ( Fig. 5k) . These gene sets have been reported to promote the cell proliferation in tumor, which is consistent with our observation that relapsed leukemia cells expressed the highest level of cell cycle genes and have the highest entropy. The 79 downregulated genes include CXCR4, DUSP1, JUNB, LST1, LTB, RPS14, RPL31 and RPS4Y2 ( Fig. 5j) , which significant enriched in IL-6 JAK STAT3 signaling, TNFA signaling pathway, IL-2 STAT5 signaling, interferon alpha response, hypoxia, inflammatory response, interferon gamma response, KRAS signaling pathway and hedgehog signaling and so on ( Fig. 5k) . Imatinib inhibits the enzymes activity of tyrosine kinase that has been shown to play a central role in the pathogenesis of human cancers. We observed the expressions of a lot of tyrosine kinases were changing during the treatment and relapse (Fig. 5l) . In summary, relapsed leukemia cells showed substructure shift and molecular difference with leukemia cells before relapse.
Leukemia progress model for patient ALL3
After analyzing the dynamics of BMMCs, we zoomed in leukemia cell subpopulations to provide biological insight on leukemia progress. The total leukemia cells from the 4 time points were classified into 6 subpopulations ( Fig. 6a) . Using CCI, we found the counterparts of the 6 leukemia cell subpopulations were B cell progenitors, namely pro-B I, pro-B II, pre-B and immature-B (Fig. 6b) . The major leukemia subpopulations at diagnosis and refractory (clusters C1 and C2) were pre-B-L and immature-B-L, while the major relapsed leukemia cells (clusters C5 and C6) were pro-B-L ( Fig. 6b) . Since pro-B is the progenitor of pre-B and pre-B is the progenitor of immature B in heathy hematopoietic lineage, we could assume that relapsed leukemia cells have increased stemness and stronger differentiation potential than leukemia cells at early stage, which is consistent with our observation that relapsed leukemia cells were in high proliferation states with the highest cell cycle activity and the highest entropy ( Fig. 5h, 5i) .
We identified single cell transcriptomic variants at different phases and found increased variants in relapsed leukemia cells (Extended Data Fig. 6b) , consistent with the expectation that mutations are progressively accumulated during cancer progress 36 . We identified the leukemia cell or its subpopulation specific variants by comparing the variants between different cell populations. Among the variants that are significantly different between leukemia cells and normal cells, chr1:11055657;T>C on SRM and chr11:9173222;A>C on DENND5A are two mutations distributed in all leukemia cell subpopulations and might play an important role in in early leukemogenesis ( Fig. 6c, 6d ).
On the other hand, the mutational alleles on IKZF1 (chr7:50382590, G>A, p.G158S) and RB1 (chr13:48409776, T>C) are extremely concentrated in relapsed leukemia cells ( Fig.   6e, 6f ), indicating these mutations raised during late phase of leukemia progress. Especially, IKZF1 G158S is a deleterious mutation associated with leukemia and is a predictor of poor outcome in ALL 37, 38 , potentially indicating that IKZF1 G158S mutation might play an functional role in the relapse of the patient.
We further separate each leukemia cell cluster into multiple subpopulations according to time points of data collection. We found the transcriptomic mutations was accumulating during the leukemia progress ( Fig. 6g) . We further constructed a hierarchical tree based on correlation coefficient of gene expression between pairwise subpopulations, choosing HSCs as root of the tree. The results showed cell subpopulations from different time points in the same cluster located on the same branch (Fig. 6h) . The major relapsed leukemia cells (ALL3.4-C5, ALL3.4-C6) and a minor leukemia cell subpopulation from early phase (ALL3.1-C5 and ALL3.2-C5) are located on the same branch ( Fig. 6h) , implicating the two subpopulations are similar to each other and potentially shared a common progenitor.
In this way, we hypothesize that the relapsed leukemia cells were derived from this minor leukemia subpopulation in early phase (ALL3.1-C5 & ALL3.2-C5) that developed resistance to Imatinib and rapidly expanded to the major subpopulations in relapse. SSBP2, a tumor suppressor gene involved in the maintenance of genome stability 39 , contains two haplotypes in the leukemia cells, namely reference haplotype and alternative haplotype.
Interestingly, reference haplotypes concentrated in early leukemia cells and normal cells, while alterative haplotypes exclusively enriched in cluster the major relapse leukemia cells (C5 and C6) ( Fig. 6i) . We found the fraction of cells with alternative haplotype in early leukemia cells (ALL3.1-C5 and ALL3.2-C5) was nearly as high as that in relapsed leukemia cells (ALL3.4-C5) ( Fig. 6j) , which strongly supports the notion that relapsed leukemia cells originated from the early minor leukemia cell subpopulation. Furthermore, the genetic variants in leukemia cells subpopulations support that relapsed leukemia cells were derived from minor leukemia cell populations from early phase (Extended Data Fig.   6d, 6e ). Based on these observations, we proposed a model for leukemia progress (Fig. 6k) , which vividly showed the dynamics of leukemia cells during diagnosis, refractory, remission and relapse.
Discussion
Distinct models have been proposed to explain the origin of leukemia heterogeneity [32] [33] [34] 
Methods
Clinical samples
In total, 18 BMMCs samples and 1 PBMC sample were analyzed in this study, with detail information ( Table S1) 
Alignment, demultiplexing, UMI Counting and normalization
The Single Cell Software Cell Ranger Suite 2 was used to perform reads alignment, barcode demultiplexing, transcripts assemblies and expression counting (https://support.10xgenomics.com). The gene-cell barcode matrix was filtered based on number of genes detected per cell (any cells with less than 500 or more than 4000 genes per cell were filtered out), and percentage of mitochondrial UMI counts (any cells with more than 10% of mitochondrial UMI counts were filtered out). UMI normalization was performed by first dividing UMI counts by the total UMI counts in each cell, followed by multiplication with the median of the total UMI counts across cells. Then, we took the natural log of the UMI counts.
Dimension reduction and clustering analysis
Dimension reduction was performed by PCA and tSNE 41 , as described in Macosko et al 4 . The highly variable genes were inferred based on normalized dispersion following Macosko et al. 4 . The top 30 principal components (PCs) were chosen for tSNE and clustering analysis, according to the explained variances. Single cell clustering was performed by k-nearest neighbor (KNN) graph and Louvain algorithm. Raw clusters with few differential expressed genes were merged to avoid excessive classification.
Inferences of hematopoietic lineages and lineage coordinated genes
Hematopoietic lineages and cell pseudotime of each hematopoietic lineage was inferred by Slingshot 19 , in which PCA was implemented and cell clusters were predefined. The cell clusters inferred by KNN graph were used as input for Slingshot to infer cell trajectories.
The constructed hematopoietic lineages was visualized by a force-directed layout in SPRING 20 , in which dimension reduction were generated by DiffusionMap 42 .
Differentially expressed genes along the pseudotime were identified using negative binomial tests in Monocle2 7,43 , with the smoothing parameter set to three degrees of freedom. For generating heatmaps of gene expression dynamics, the normalized UMI counts were log transformed and smoothed using Loess regression with the degree of smoothing (span) set to 0.75. Heatmaps for gene expression profile clustering were generated using heatmap function in R. While the other graphics were generated using ggplot2 in R.
Gene regulatory network (GRN) score
The GRN score 23 reflect the regulator-target relationships in the context of trajectory progression, which ranks transcriptional regulators based on their correlation with the trajectory, the correlation with their predicted targets, and the extent to which target genes are regulated during the trajectory, which defined as below,
where GRNi,j is the GRN score for regulator i along trajectory j. ci,j is the mutual information between transcriptional regulator i and trajectory j, mt,j is the average mutual information between predicted target gene t and trajectory j, nj is the number of predicted targets regulated along trajectory j.
Lineage coordinated TF networks
Human transcription factors (TFs) were downloaded from TcoF-DB v2 44 . Lineage coordinated TF networks were constructed following Fletcher et al. 45 
Gene sets enrichment analysis (GSEA)
GSEA determines whether a priori defined set of genes shows statistically significant differences between two biological states. The original GSEA was developed for geneexpression assays of bulk data 27, 46 , which may lost accuracy when directly implement on scRNA-RNA data. In order to take advantage of thousands of single cell transcriptomes, we designed an approach as below: (1) Gene expression was averaged from 30 random cells from each cluster due to the high dropout rates of scRNA-seq data. Genes were ranked according to their expression level for each set of cells. (2) Recovery curve was created by walking down the gene list, and steps were increased when we encounter a gene in the gene set. Area under the curve (AUC) was computed as the indicator of enrichment for a certain gene set. And only AUC of top 5000 ranked genes was considered. (3) To compare the different enrichment of two cell populations for a gene set, we calculate the Zscore of AUC in one cell population relative to the AUC distribution in another cell population. Gene sets from Msigdb3.0 (Molecular Signatures Database) were used for analysis by our approach.
Counterpart composite index (CCI)
It is interesting to systematically compare the developmental trajectories of leukemia cells with that of healthy hematopoietic cells. However, searching the counterpart of a leukemia cell subpopulation in healthy hematopoietic cells is very challenging due to the significant difference between leukemia cells and healthy hematopoietic cells. Based on simulated data, our initial analyses showed that different approaches may produce different results.
However, different statistics have much higher probability to generate consistent result when two cell populations have counterpart relationship than these when two cell populations have uncertain relationship. Thus, the composite likelihood of the statistics is the highest when two cell populations have counterpart relationship. Here, we developed an approach, called counterpart composite index (CCI), to search for healthy counterpart of each leukemia cell subpopulation by integrating multiple statistics to project leukemia cells into healthy hematopoietic cells. CCI integrates Euclidean distance of gene expression, correlation of gene expression, weighted distance in top PCs and difference of gene set enrichment for composite likelihood statistical framework as below:
In which, Si is the score of measurement i, Rj is the candidate reference cell population j, Nr is the number of reference cell population, Nm is the number of composite measurements in CCI.
The computational details of each statistics were described as follows:
1) Euclidean distance of gene expression
Considering the prevalent of dropouts and sample size asymmetry, gene expression level was averaged from 30 random cells from each population. The sampling was repeat by ten thousand times for each pairwise populations, from which the median value of expression difference was used as the statistical measurement of two populations. In the meanwhile, pairwise statistical distribution was built from the sampling and computations.
2) Correlation of gene expression
Spearman's rank correlation coefficient between cell populations was calculated to measure the similarity of gene expression. The sampling and distribution construction were following the same strategy as above.
3) Weighted distance in top PCs
The top principal components, which could represent the distance between cell populations or even single cells, were integrated into CCI. Euclidean distance in embedding space defined by top 30 eigenvectors was weighted by their explained variances.
4) Difference of gene set enrichment
It is well known that cells with similar function have similar biological process and show similar gene set enrichment. Recovery curve of each gene set was constructed and AUC value of top 5000 ranks were used for the indication of cell similarity. Averaged gene expression from 30 random cells of each population were used to calculate the responding AUCs of 50 hallmark gene sets from Msigdb. Median value and statistical distribution were derived from ten thousand of samplings.
Facilitated by the comprehensive cell atlas of BMMCs and HSPCs, we could identify the healthy counterparts of each leukemia cell subpopulation in HSPCs using CCI, which could greatly benefit our understanding of the progression of leukemia.
Identifying the genetic variants in single cell transcriptome
There are a few reads in each locus of the single transcriptomic data; thus, it is very difficult to directly detect the cell specific variants. In order to reliably detect single-cell expressed specific variants, reads from every single individual were pooled to do variants calling. An in-house script was used to assign each single cell with its associated variants, by checking the variant on indexed reads. To reduce the artifacts and false positives, we used following criteria to filter the cell variants: 1) not missing in at least 20 cells; 2) at least 5 cells with 2 reads sequenced; 3) variants observed in at least 3 cells. We found that the number of detected transcript mutations in each leukemia patient was much higher than that in each healthy individual, partially due to increased number of expressed genes in leukemia cells.
The single nucleotide variations (SNVs) identification could be affected by the copy number variations (CNVs) change in studied regions. We identified genome wide CNVs in leukemia cells, which could affect the genome-wide identification of SNVs. Therefore, we used the deletion regions from the bulk data to filter the covered homozygous SNVs, as well as the associated signals. CNVnator (v0.3.2) was used to call CNVs from the wholegenome sequencing data, with a depth of ~30X, of ALL3. The somatic CNVs was then generated by comparing CNVs at different time points to CNVs detected from its saliva sample.
Haplotype tracing
We observed a sequential of homozygous variants of SSBP2 from the major relapsed leukemia cell subpopulation ALL3.4-C5, which is the alternative haplotype of SSBP2. We analyzed 39 polymorphisms in SSBP2 to investigate the distribution of the alternative haplotype in different cell populations. Any cell with more than 5 loci showing the same alleles as that in alterative haplotype (P<0.05) were thought contained the alterative haplotype. Tables S1. The samples information. Fig. 1. Basic 
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